1 unknown. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Heart Failure With Reduced Ejection Fraction: new trials by email Literature Review of Heart Failure With Reduced Ejection Fraction trials Research Report on Heart Failure With Reduced Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID, Empagliflozin 10 MG OD - Congenital Heart Disease, Heart Failure | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cardiologia Ignacio Chavez | 160 | 2023-02-06 | 2022-11-02 |
Heart Defects, Congenital (1) · Heart Failure (1)
Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Heart Diseases (1)
BID protein, human (1) · Valsartan (1) · empagliflozin (1) · sacubitril (1) · sacubitril and valsartan sodium hydrate drug combination (1)
Instituto Nacional de Cardiologia Ignacio Chavez (1)
Mexico (1)
Carlos Guizar-Sanchez, MD (1) · Edgar Garcia-Cruz, MD (1) · Gian Jimenez-Rodriguez, MD (1) · Montserrat Villalobos-Pedroza, MD (1)
PMID 30520545, PMID 32865377, PMID 33186500, PMID 33447845, PMID 33832352